The influence of renal function on clinical pharmacokinetics of XXXX .

@entity1 @entity8 @entity101 @entity23703 @entity177
Investigations were carried out on 24 @entity101 or borderline @entity101 @entity1 with different degrees of renal function. Eight had normal renal function [glomerular filtration rate (GFR) greater than 90 ml/min], 8 moderate (GFR 30 to 60 ml/min) and 8 severe @entity8 (GFR less than 30 ml/min). All @entity1 were given @entity23703 0.3mg once daily for 7 days and both pharmacokinetic and pharmacodynamic data were determined. During @entity23703 treatment plasma elimination half-life, area under the plasma concentration-time curve (AUC) and apparent total clearance (CLT) showed statistically significant differences among @entity1 in the 3 groups. Elimination half-life was 2.6 +/- 0.9 hours in @entity1 with a GFR greater than 90 ml/min and increased to 6.9 +/- 3.7 hours in those with a GFR less than 30 ml/min (mean +/- SD; p = 0.012). Correspondingly, AUC0-24 h rose from 5.4 +/- 2.7 to 17.2 +/- 7.9 micrograms/L . h (p = 0.001), and CLT decreased from 1150 +/- 602.l ml/min to 369 +/- 227.6 ml/min (p = 0.001). These data suggest that once-daily administration of 0.3mg @entity23703 may be appropriate in @entity1 with @entity8 . Independent of renal function, @entity23703 was well tolerated in 22 of 24 @entity1 . No deterioration in renal function as a consequence of the use of @entity23703 was found. Thus, in @entity1 with @entity177 , dosage of @entity23703 should be individually titrated according to the desired clinical response, as is recommended for @entity101 @entity1 without @entity8 .
